October 24, 2021 01:13 (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Lakhimpur Kheri violence: Three more arrested, say sources | Amit Shah's Mission Kashmir begins with visit to slain cop’s family | Tamil film Koozhangal India's official entry into Oscars 2022 | India records 16,326 new COVID-19 cases in past 24 hours | Mamata Banerjee calls upon individuals, organisations, political parties to join forces to defeat BJP
Zydus Cadila receives final approval from USFDA for Deferasirox Tablets
Image Credit: UNI

Zydus Cadila receives final approval from USFDA for Deferasirox Tablets

India Blooms News Service | @indiablooms | 16 Jun 2020, 01:58 pm

Mumbai/UNI: Pharma major, Zydus Cadila on Tuesday said it has received final approval from the USFDA to market Deferasirox Tablets in the strengths of 90 mg, 180 mg and 360 mg.

Deferasirox binds to iron and removes it from the bloodstream. It is used to treat iron overload caused by blood transfusions in adults and children who are at least 2 years old. It is also used to treat chronic iron overload syndrome caused by a genetic blood disorder (non-transfusion dependent thalassemia) in adults and children who are at least 10 years old.

The drug will be manufactured at the group's manufacturing facility at SEZ, Anmedabad.

The group now has 291 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04.